Varenicline Effects In Schizophrenic Smokers

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nathan Kline Institute for Psychiatric Research
• Collaborator: University of Illinois at Chicago
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis

• Recent History of Cigarette smoking

• Ages 18-65